BACKGROUND: We sought to define current incidence trends and outcomes for children with lung and bronchus tumors. METHODS: The SEER registry was queried from 1973 to 2004 for all patients with pulmonary tumors less than 20 y of age. RESULTS: Overall, 160 patients were identified. The age-adjusted incidence has remained stable at 0.049 per 100,000 persons. The median age at diagnosis was 16 y. Whites had the highest age-adjusted population incidence at 0.056 per 100,000. Most tumors arose in the lower lobe (37%), followed by the upper lobe (31.2%). The most common histology was endocrine tumor (51.6%), followed by sarcoma (11%), and mucoepidermoid tumor (9%). Overall survival was greater than 381 mo with a 15-y survival of 65%. Males had better survival (>381 versus 288 months). Endocrine and mucoepidermoid tumors had the best survival. Small cell carcinoma had the worst median survival at less than 5 mo. Squamous cell carcinoma and adenocarcinoma both had a 14-mo median survival. Median survival for nonsurgically treated patients was 14 mo with a 10-y survival rate of 32%. Surgery improved the 10-y survival to 75% (P<0.0001). Multivariate analysis demonstrated nonsurgical treatment and nonendocrine tumor histology to be independent prognostic factors of death. CONCLUSION: The incidence of pediatric lung cancer remains stable. Several factors, including nonsurgical treatment and nonendocrine tumors confer a poor prognosis. Early diagnosis and surgical therapy provide the best chance for survival.
BACKGROUND: We sought to define current incidence trends and outcomes for children with lung and bronchus tumors. METHODS: The SEER registry was queried from 1973 to 2004 for all patients with pulmonary tumors less than 20 y of age. RESULTS: Overall, 160 patients were identified. The age-adjusted incidence has remained stable at 0.049 per 100,000 persons. The median age at diagnosis was 16 y. Whites had the highest age-adjusted population incidence at 0.056 per 100,000. Most tumors arose in the lower lobe (37%), followed by the upper lobe (31.2%). The most common histology was endocrine tumor (51.6%), followed by sarcoma (11%), and mucoepidermoid tumor (9%). Overall survival was greater than 381 mo with a 15-y survival of 65%. Males had better survival (>381 versus 288 months). Endocrine and mucoepidermoid tumors had the best survival. Small cell carcinoma had the worst median survival at less than 5 mo. Squamous cell carcinoma and adenocarcinoma both had a 14-mo median survival. Median survival for nonsurgically treated patients was 14 mo with a 10-y survival rate of 32%. Surgery improved the 10-y survival to 75% (P<0.0001). Multivariate analysis demonstrated nonsurgical treatment and nonendocrine tumor histology to be independent prognostic factors of death. CONCLUSION: The incidence of pediatric lung cancer remains stable. Several factors, including nonsurgical treatment and nonendocrine tumors confer a poor prognosis. Early diagnosis and surgical therapy provide the best chance for survival.
Authors: Bassan J Allan; Punam P Parikh; Sofia Diaz; Eduardo A Perez; Holly L Neville; Juan E Sola Journal: HPB (Oxford) Date: 2013-04-22 Impact factor: 3.647
Authors: Sergio Jaramillo; Yesenia Rojas; Bethany J Slater; Michael L Baker; M John Hicks; Jodi A Muscal; Timothy J Vece; David E Wesson; Jed G Nuchtern Journal: Pediatr Surg Int Date: 2016-01-20 Impact factor: 1.827
Authors: Abhijeet Dharmaji Sawant; Vijayraj S Patil; Pranjal M Gugalia; Rajiv Kumar; Sabita Jiwnani; George Karimundackal; C S Pramesh Journal: Lung India Date: 2018 Jan-Feb
Authors: Hyun Ju Cho; Jisun Yoon; Eun Lee; Yoon Se Lee; Sang Yoon Kim; Jong Lyel Roh; Dong Kwan Kim; Se Hoon Choi; Seung Il Park; Yong Hee Kim; Kyung Nam Koh; Ho Joon Im; Jong Jin Seo; Soo Jong Hong; Jinho Yu Journal: J Korean Med Sci Date: 2017-08 Impact factor: 2.153
Authors: Giacomina Megaro; Evelina Miele; Gian Paolo Spinelli; Iside Alessi; Giada Del Baldo; Raffaele Cozza; Ida Russo; Maria Debora De Pasquale; Maria Giuseppina Cefalo; Paolo Tomà; Andrea Carai; Valentina Di Ruscio; Maria Antonietta De Ioris; Angela Mastronuzzi Journal: Cancer Rep (Hoboken) Date: 2022-01-28